Albireo Pharma, Inc.

NasdaqCM:ALBO Stock Report

Market Cap: US$921.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma (ALBO) Stock Overview

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. More details

ALBO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALBO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Albireo Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Albireo Pharma
Historical stock prices
Current Share PriceUS$44.15
52 Week HighUS$45.23
52 Week LowUS$16.02
Beta1.04
1 Month Change-1.23%
3 Month Change85.66%
1 Year Change66.73%
3 Year Change98.69%
5 Year Change28.53%
Change since IPO202.40%

Recent News & Updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Recent updates

We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Jan 02
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely

Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Oct 25
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt

Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

Oct 11

Albireo Pharma: Assessing The Sagard Deal

Oct 03

Albireo gains on royalty agreement for pruritus therapy

Sep 22

Albireo gets reimbursed access to liver disease drug Bylvay in Italy

Sep 06

These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Aug 23
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts

Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M

Aug 15

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

Jul 22

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

May 10
Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

Albireo: A Speculative Play With Upside

May 03

Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Feb 02
Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?

Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Jan 31

Albireo: Reasons For A Successful Transformation Into A Commercial Company

Nov 24

Albireo Pharma: A Post Approval Assessment

Aug 09

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Jun 21

Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Jun 11
Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year

Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Feb 27
Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts

Shareholder Returns

ALBOUS BiotechsUS Market
7D1.2%0.1%3.4%
1Y66.7%-10.9%13.7%

Return vs Industry: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.

Return vs Market: ALBO exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is ALBO's price volatile compared to industry and market?
ALBO volatility
ALBO Average Weekly Movement27.3%
Biotechs Industry Average Movement12.1%
Market Average Movement7.7%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market4.0%

Stable Share Price: ALBO's share price has been volatile over the past 3 months.

Volatility Over Time: ALBO's weekly volatility has increased from 17% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a130Ron Cooperwww.albireopharma.com

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.

Albireo Pharma, Inc. Fundamentals Summary

How do Albireo Pharma's earnings and revenue compare to its market cap?
ALBO fundamental statistics
Market capUS$921.13m
Earnings (TTM)-US$131.14m
Revenue (TTM)US$57.39m
16.1x
P/S Ratio
-7.0x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALBO income statement (TTM)
RevenueUS$57.39m
Cost of RevenueUS$2.55m
Gross ProfitUS$54.84m
Other ExpensesUS$185.99m
Earnings-US$131.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.29
Gross Margin95.56%
Net Profit Margin-228.51%
Debt/Equity Ratio0%

How did ALBO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/03 02:33
End of Day Share Price 2023/03/02 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Albireo Pharma, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
null nullGuggenheim Securities, LLC
Seamus FernandezGuggenheim Securities, LLC